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driven by declined annual family income ($56,139 in 2007 to $52,811 in 2010). This 
increasing trend was observed particularly among diabetic patients with low family 
income (2.3% in 2007 to 5.0% in 2010). In the contrast, the financial burden of medica-
tions was relieved for those aged younger than 18 years old (1.8% in 2007 to 0.3% in 
2010). Patients receiving insulins and thiazolidinediones had higher out-of-pocket 
spending as well as financial burden than those used other medications to treat 
diabetes. ConClusions: Patients’ drug costs were reduced successfully between 
2007 and 2010. However, the financial burden of prescription drugs for diabetes 
increased due to decreased family income. Since the use of prescription drugs is a 
vital part of diabetes management, more efforts should be directed to patients with 
low family income in order to improve affordability of prescription drugs.
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objeCtives: To examine the relative contribution of predisposing, enabling, need, 
and external environment factors to the excess health care expenditures associ-
ated with thyroid disorders among individuals with diabetes, compared to indi-
viduals with diabetes and without thyroid disorders. Methods: Cross-sectional 
study design with data on adults over 20 years of age with diabetes (N = 4,920) from 
two years (2009 and 2011) of the Medical Expenditure Panel Survey (MEPS) were 
used. Ordinary least square regressions on log-transformed total expenditures 
were performed to estimate the excess expenditures associated with thyroid dis-
orders after controlling for predisposing, enabling, external environment, life-style 
and need factors as defined framework of the Anderson Behavior and Healthcare 
Utilization Model. Post-regression Blinder-Oaxaca (BO) decomposition analysis was 
performed to examine the relative contribution of factors in explaining the average 
differences in health care expenditures between the two groups. Results: Among 
individuals with diabetes, those with thyroid disorders had greater annual mean 
expenditure compared to those without thyroid disorders ($ 14,289 vs. $10,636, p < 
0.001). After accounting for the predisposing, enabling, external environment, life-
style and need factors, those with thyroid disorders had 15% greater health care 
expenditures compared to those without thyroid disorders. The BO decomposition 
analysis revealed that predisposing, enabling, external environment, life-style and 
need factors explained 63% of the excess health care expenditures among indi-
viduals with thyroid disorders. The excess health care expenditures between the 
groups was predominantly explained by need-factors (43%). Presence of cardiovas-
cular diseases, depression, arthritis, and cancer explained the excess expenditures 
between the groups among the need-factors. ConClusions: Presence of thyroid 
disorders is associated with greater health care expenditures among individuals 
with diabetes. Co-management of co-occurring conditions may reduce the excess 
health care expenditures among individuals with thyroid disorders and diabetes.
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objeCtives: To compare the burden of disease attributable to diabetes expressed in 
Disability Adjusted Life Years (DALYs) for five European countries in 2010. Methods: 
DALYs lost to diabetes as the sum of years of life lost and years lived with disability 
were estimated by gender and age using country-specific epidemiological data and 
global disability weights. Data from various secondary sources were combined to 
estimate health loss due to diabetes for France, Germany, Italy, Spain and the UK. 
National statistical databases were used and in case necessary, community studies 
were used to derive the prevalence of diabetes by gender and age group which were 
weighted proportionately for a national population burden of disease estimate. All 
identified data were adapted to the Global Burden of Disease methodology (2010) 
to calculate the burden attributable to diabetes. No age weighting and discounting 
was applied. Sensitivity to different sources of variation was examined. Results: 
Germany and Italy lost the largest number of DALYs due to diabetes with 5.9 and 5.8 
per 1,000 inhabitants respectively, followed by Spain (4.4), France (3.7) and the UK 
(2.9). The highest burden was caused by mortality due to diabetes, with the excep-
tion of the UK, for which the burden due to disability of diabetes was higher. This 
may be explained by the way of reporting death in the UK. Mean DALYs lost were 
higher for women in Germany, Italy and Spain and showed to increase with age for 
all countries. Sensitivity analysis in variation in disability weights and uncertainty 
in epidemiological data showed to have effects on DALYs lost. ConClusions: In 
spite of data limitations, the estimates reported here show that DALY loss due to 
diabetes imposes a substantial burden on countries. Cross-national variation in 
disease epidemiology was the largest source of variation in the burden of diabetes 
between countries.
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objeCtives: Alogliptin-pioglitazone (alo-pio) reduces HbA1c levels in treatment-
naïve Type 2 diabetic (T2DM) patients, or those inadequately controlled by mon-
otherapy. Yet, the percentage of patients on alo-pio continuing to meet HbA1c 
thresholds suggested by the National Committee for Quality Assurance (NCQA) 
is unclear but may be important to accountable care organizations (ACOs). This 
analysis examined whether NCQA recognition, aligning with > 40% of patients 
below 7%, > 60% below 8%, and ≤ 15% above 9% HbA1c, is achievable. Methods: 
ied across GLP-1RAs and analyses (ranging from 2.162 [p< 0.001] for exenatide vs. 
exenatide QW among initial adherers, to 0.986 [p= 0.798] for liraglutide 1.8mg vs. 
exenatide QW among initial adherers, to 0.869 [p< 0.001] for liraglutide 1.8mg vs. 
exenatide QW among all patients). ConClusions: Among patients newly initiat-
ing exenatide QW, exenatide, or liraglutide, adherence was consistently highest for 
exenatide QW, while non-persistence varied by analyzed group.
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objeCtives: The personal and economic burden of diabetes is substantial and 
growing in Japan due to its aging population. This study aimed to review the avail-
able literature on the usual treatment of adults with type 2 diabetes (T2DM) in 
Japan. Methods: Systematic search of the scientific literature was performed on 
MEDLINE and EMBASE databases to identify publications about usual care of dia-
betes in Japan written in English or Japanese and published between January 2000 
and May 2013. Included keywords were diabetes mellitus, drug therapy and Japan. 
Randomized clinical trials, comparative or interventional studies were excluded. 
Of 17 publications that met search criteria, 13 pertained to adults with T2DM, of 
which 9 contained original survey data and 4 were literature reviews. Results: 
Almost all of the available data was at least 7 years old. Based on data from 2000 to 
2002, the use of oral anti-diabetic drugs (OAD) alone was the most prevalent treat-
ment option (51.4%), followed by diet alone (25.4%), insulin alone (15.4%), and OAD 
with insulin (7.8%). Although overall, sulfonylureas was the preferred class of OAD 
(61-67%), its use among treatment initiators has dramatically declined from 40% to 
22% following the introduction of dipeptidyl peptidase-4 inhibitors (DPP4) in 2009. 
Since then, the prescription rate of DPP4 increased to nearly 40% due to its perceived 
better safety. ConClusions: Available data on the treatment of diabetes in usual 
care in Japan is rather sparse and not recent. Results indicate that the treatment 
of adults with T2DM in Japan with OAD and insulin is rather similar to that in the 
US and Europe, although the specific OAD in Japan is different. Further research is 
needed on the usual treatment of diabetes in Japan, considering increased longev-
ity, lifestyle changes, ongoing introduction of new medications, changes in disease 
management practices and increased economic concerns.
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objeCtives: Type II Diabetes Mellitus (DM) is exponentially growing in Chile. A 
recent reform aimed at reducing inequities in health care in the country, but the 
gap between social groups continues to grow. We aimed at exploring the exist-
ence of under-diagnosis of type II DM in adult population in Chile. Methods: 
Secondary analysis of cross-sectional Chilean Health Survey 2009-2010 (n= 4767 
adults, weighted sample: 13,347,316). We compared the proportion of adult popula-
tion self-reporting type II DM against the proportion with altered fasting glycae-
mia (value > 126mg/dl, Chi-square test) and then assessed the socio-demographic 
characteristics of those having the condition but ignoring it. For population-rep-
resentative analysis we used Stata 12.0. Results: 48.7% sample were men, mean 
age was 42 years (s.d.:40.8), 56.9% had middle socioeconomic status (SES), followed 
by high and low (18.6%, 24.5%) and 87% lived in urban areas. A 7.8% reported being 
diagnosed with type II DM. There was a significantly higher rate of self-reported 
DM among women than men (5.0% versus 2.8%) and people living in urban versus 
rural settings (6.7% and 1.0%). People with self-reported DM were on average 17 
years older than people without previous diagnosis (mean:57.1). According to lab 
results, 8.4% of the total adult population had type II DM. From this group, over half 
(4.6%) had not been diagnosed with this condition before, representing over 280,000 
people. They are mostly middle-aged men (mean age:46.6) from low and middle SES 
and living in urban areas. ConClusions: We found an under-diagnosis of type II 
DM among middle-aged male adults in Chile. Few recent studies report the urgent 
need to develop community-based strategies to enhance male use of health care, 
particularly to pursue screening consultations even when feeling healthy. This study 
supports such initiative and challenges the complex relationship between gender 
and SES, which could be further explored in Chile.
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objeCtives: To examine the changes in out-of-pocket spending and financial 
burden of prescription drugs for diabetes between 2007 and 2010. Methods: The 
Medical Expenditure Panel Survey for 2007-2010 was analyzed for patients with 
diabetes. Out-of-pocket spending was defined as any self-reported coinsurance and 
deductibles, as well as payments for prescription medications that were not covered 
by insurance. Financial burden for prescription drugs was measured using the pro-
portion of out-of-pocket expenditures divided by total family income in a given year. 
Expenditures for each year were adjusted using Consumer Price Index. Results: 
The out-of-pocket spending for prescription drugs for treating diabetes was dropped 
significantly from $232.5 in 2007 to $197.9 in 2010, while the total expenditure for 
prescription drugs for diabetes increased dramatically from $875.9 to $1026.3 dur-
ing the same period. This declined out-of-pocket spending was observed across 
different age, gender, and racial groups. From 2007 to 2010, the financial burden 
of prescriptions drugs for diabetes increased from 0.8% to 1.1%, which was largely 
